Theravance financial flexibility, assets underappreciated, says Piper Jaffray

Piper Jaffray analyst Tyler Van Buren says recent meetings with Theravance Biopharma management support his Overweight rating on the shares. The Trelegy royalty stream could potentially be monetized in the near-term as a source of non-dilutive financing, which would alleviate concerns regarding the need for cash, a significant portion of the current bear thesis, Van Buren tells investors in a research note. Further, he notes that management remains confident in a Yupelri approval on November 13. The analyst continues to recommend that investors own Theravance shares as he believes both its financial flexibility and current assets are underappreciated.
https://thefly.com/landingPageNews.php?id=2796195